Treatment

Pred Forte 1% w/v clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum- Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
This study, called MIRASOL, is testing a new drug, Mirvetuximab Soravtansine, against standard chemotherapy for advanced ovarian, peritoneal, or fallopian tube cancers that are resistant to platinum-based treatments and have high folate receptor-alpha.
For: Platinum-Resistant Advanced High-Grade Epithelial Ovarian · Primary Peritoneal · or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
France